Regenerative medicine company providing advanced wound care and surgical biologics solutions.
Organogenesis Holdings Inc. is a prominent player in the regenerative medicine sector, specializing in the development, manufacturing, and commercialization of innovative solutions tailored for the advanced wound care, surgical, and sports medicine markets across the United States.
At the forefront of its advanced wound care portfolio are products like Affinity, which preserves viable cells, growth factors, cytokines, and ECM proteins from amniotic membrane tissue to facilitate healing. Apligraf, another key offering, is a bioengineered living cell therapy that produces a spectrum of cytokines and growth factors essential for wound repair. Dermagraft, on the other hand, harnesses bioengineered human collagen, ECM proteins, and cytokines to promote tissue regeneration.
Organogenesis's surgical and sports medicine solutions include NuCel, a dehydrated placental tissue used surgically to support native tissue healing, and ReNu, a cryopreserved suspension aiding in the healing of soft tissues. Products like FiberOS and OCMP serve as bone void fillers primarily used in orthopedic and neurosurgical applications.
In its pipeline, Organogenesis continues to innovate with products like PuraPly XT and PuraPly MZ for treating chronic, acute, and open wounds, and PuraForce, a bioengineered porcine collagen surgical matrix for soft tissue reinforcement. TransCyte, a bioengineered tissue designed for partial thickness burns, further expands the company's therapeutic offerings.
Organogenesis serves a broad spectrum of healthcare providers including hospitals, wound care centers, government facilities, ambulatory service centers, and physician offices through a dedicated sales force and independent agencies. Founded in 1985 and headquartered in Canton, Massachusetts, the company remains committed to advancing regenerative medicine solutions that improve patient outcomes and quality of life.